Kidney cancer Clinical Trials
Recruiting kidney cancer studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.
Clinical trials study new ways to prevent, detect, or treat kidney cancer. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting kidney cancer studies with sites across the US; use the location tools to find ones near you.
What to expect
- Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
- Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
- No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.
Recruiting kidney cancer trials
Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
A Study of a Side Effects and Resource Navigation Program for People With Cancer
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors
Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Distance-Based Exercise to Preserve Function and Prevent Disability
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Retifanlimab and Ruxolitinib In Solid Malignancies
Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
Tumor Rupture During Robotic Partial Nephrectomy
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
DESTINY-PANTUMOUR04
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
IDOV-Immune for Advanced Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.
Proteomic Analysis of Patients Undergoing Bariatric Surgery
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Designing Visual Tools to Enhance Cancer Surgeon Decision-making
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
Brodalumab in the Treatment of Immune-Related Adverse Events
Rein 3D PRINT MECHANICS
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment
Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma
Study of Post-operative Complications After Laparoscopic Outpatient Nephrectomy
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Drug Screening Using Novel IMD in Renal Cell Carcinoma
Delving Into Participation Trends in Renal Cell Carcinoma Studies
Kidney cancer clinical trials — common questions
Are kidney cancer clinical trials free to join?
Yes. Participating in a kidney cancer clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.
Who can join a kidney cancer clinical trial?
Each kidney cancer study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.
How do I find a kidney cancer trial near me?
Use the location controls above. We'll show recruiting kidney cancer trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.
How many kidney cancer trials are recruiting right now?
We're currently tracking roughly 110 recruiting kidney cancer trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.
Looking for a specific location? Browse trials by city and state.